Top

01-28-2017 | Hypertension | Review | Article

Salt and hypertension in diabetes

Journal: Diabetology International

Author: Takashi Uzu

Publisher: Springer Japan

Abstract

Worldwide, the number of patients with diabetes is increasing. Adults with diabetes have a two- to threefold increased risk of heart attack and stroke, and diabetic nephropathy is a leading cause of end-stage renal failure. Salt sensitivity of blood pressure is reported to be elevated in patients with diabetes. Hyperinsulinemia, hyperglycemia, and an activated sympathetic nervous system play key roles in the genesis of salt-sensitive blood pressure in individuals who are obese and/or have type 2 diabetes. In this review, I summarize previous research performed to improve our understanding of the relationship between salt and hypertension in diabetic patients.

Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37(4):253–390.PubMedCrossRef

Izzo R, de Simone G, Chinali M, Iaccarino G, Trimarco V, Rozza F, Giudice R, Trimarco B, De Luca N. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32(5):845–50.PubMedPubMedCentralCrossRef

Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580–5.PubMedCrossRef

Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Utr Metab Cardiovasc Dis. 2000;10(5):287–94.

Law MR, Frost CD, Wald NJ. Dietary salt and blood pressure. J Hypertens Suppl. 1991;9(6):S37–41 (discussion S47–S49).PubMedCrossRef

Kimura G, Frem GJ. Brenner BM Renal mechanisms of salt sensitivity in hypertension. Curr Opin Nephrol Hypertens. 1994;3(1):1–12.PubMedCrossRef

Uzu T, Sakaguchi M, Yokomaku Y, Kume S, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M, Kashiwagi A. Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol. 2009;13(4):300–6.

Miller JZ, Weinberger MH, Daugherty SA, Fineberg NS, Christian JC, Grim CE. Heterogeneity of blood pressure response to dietary sodium restriction in normotensive adults. J Chronic Dis. 1987;40(3):245–50.PubMedCrossRef

Uzu T, Kimura G, Yamauchi A, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Nishio Y, Maegawa H, Koya D, Haneda M, Kashiwagi A. Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertension. J Hypertens. 2006;24(8):1627–32.PubMedCrossRef

10.

Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R, D’Elia L, Russo O, Versiero M, Farinaro E, Cappuccio FP. Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens. 2006;24(8):1633–9.PubMedCrossRef

11.

Barbato A, Cappuccio FP, Folkerd EJ, Strazzullo P, Sampson B, Cook DG, Alberti KG. Metabolic syndrome and renal sodium handling in three ethnic groups living in England. Diabetologia. 2004;47(1):40–6.PubMedCrossRef

12.

Rocchini AP, Katch V, Kveselis D, Moorehead C, Martin M, Lampman R, Gregory M. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14(4):367–74.PubMedCrossRef

13.

Tiwari S, Sharma N, Gill PS, Igarashi P, Kahn CR, Wade JB, Ecelbarger CM. Impaired sodium excretion and increased blood pressure in mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci USA. 2008;105(17):6469–74.PubMedPubMedCentralCrossRef

14.

Grassi G, Colombo M, Seravalle G, Spaziani D, Mancia G. Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure. Hypertension. 1998;31(1):64–7.PubMedCrossRef

15.

Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96(10):3423–9.PubMedCrossRef

16.

Mu S, Shimosawa T, Ogura S, Wang H, Uetake Y, Kawakami-Mori F, Marumo T, Yatomi Y, Geller DS, Tanaka H, Fujita T. Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med. 2011;17(5):573–80.PubMedCrossRef

17.

Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol. 2014;25(6):1148–55.PubMedPubMedCentralCrossRef

18.

Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab. 2000;26(Suppl 4):8–14.PubMed

19.

Ellis EN, Wiegmann TB, Savin VJ. Diminished glomerular capillary hydraulic conductivity precedes morphologic changes in experimental diabetes mellitus in the rat. Diabetes. 1992;41(9):1106–12.PubMedCrossRef

20.

Tomlanovich S, Deen WM, Jones HW 3rd, Schwartz HC, Myers BD. Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diabetes. 1987;36(5):556–65.PubMedCrossRef

21.

Uzu T, Kazembe FS, Ishikawa K, Nakamura S, Inenaga T, Kimura G. High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension. 1996;28(1):139–42.PubMedCrossRef

22.

Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation. 1997;96(6):1859–62.PubMedCrossRef

23.

Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H. Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res. 2003;26(9):669–76.PubMedCrossRef

24.

Flores L, Janka M, Canivell S, Jiménez A, Vidal J. Glucose abnormalities associated with impaired nocturnal fall in blood pressure in normotensive severely obese patients. Diabetes Res Clin Pract. 2013;101(2):153–8.PubMedCrossRef

25.

Uzu T, Nakao K, Kume S, Araki H, Isshiki K, Araki S, Kawai H, Ugi S, Kashiwagi A, Maegawa H. High sodium intake is associated with masked hypertension in Japanese patients with type 2 diabetes and treated hypertension. Am J Hypertens. 2012;25(11):1170–4.PubMedCrossRef

26.

Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA, TONE, Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998;279:839–46.PubMedCrossRef

27.

American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2017;40(Suppl 1).

28.

Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, Jerums G. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34(3):703–9. doi:10.2337/dc10-1723.PubMedPubMedCentralCrossRef

29.

Araki S, Haneda M, Koya D, Kondo K, Tanaka S, Arima H, Kume S, Nakazawa J, Chin-Kanasaki M, Ugi S, Kawai H, Araki H, Uzu T, Maegawa H. Urinary potassium excretion and renal and cardiovascular complications in patients with type 2 diabetes and normal renal function. Clin J Am Soc Nephrol. 2015;10(12):2152–8.PubMedPubMedCentralCrossRef

30.

Suckling RJ, He FJ, Markandu ND, MacGregor GA. Modest salt reduction lowers blood pressure and albumin excretion in impaired glucose tolerance and type 2 diabetes mellitus: a randomized double-blind trial. Hypertension. 2016;67(6):1189–95.PubMed

31.

Tanaka T, Nangaku M, Nishiyama A. The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-4 inhibitors. Curr Opin Nephrol Hypertens. 2011;2(5):476–81.CrossRef

32.

Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009;380(1):44–9.PubMedCrossRef

33.

Sharkovska Y, Reichetzeder C, Alter M, Tsuprykov O, Bachmann S, Secher T, Klein T, Hocher B. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens. 2014;32(11):2211–23.PubMedCrossRef

34.

Nilsson PM, Diez J. DPP-4 inhibition and blood pressure lowering in perspective. J Hypertens. 2016;34(2):184–7.PubMedCrossRef

35.

Sufiun A, Rafiq K, Fujisawa Y, Rahman A, Mori H, Nakano D, Kobori H, Ohmori K, Masaki T, Kohno M, Nishiyama A. Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats. Hypertens Res. 2015;38(4):237–43.PubMedPubMedCentralCrossRef

36.

Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737–49.PubMedCrossRef

37.

Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, Menge BA, Forst T, Kapitza C. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized. Open-label trial. Diabetes Care. 2015;38(7):1263–73.PubMedCrossRef

38.

Kimura G. Diuretic action of sodium–glucose cotransporter 2 inhibitors and its importance in the management of heart failure. Circ J. 2016;80(11):2277–81.

39.

Greger R, Velázquez H. The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism. Kidney Int. 1987;31(2):590–6.PubMedCrossRef

40.

Kimura G. Importance of inhibiting sodium–glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis. J Am Soc Hypertens. 2016;10(3):271–8.PubMedCrossRef

41.

Pessoa TD, Campos LC, Carraro-Lacroix L, Girardi AC, Malnic G. Functional role of glucose metabolism, osmotic stress, and sodium–glucose cotransporter isoform-mediated transport on Na⁺/H⁺ exchanger isoform 3 activity in the renal proximal tubule. J Am Soc Nephrol. 2014;25(9):2028–39. doi:10.1681/ASN.2013060588 (Epub 2014 Mar 20).

42.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef

43.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.PubMedCrossRef

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

Abstract

Be confident that your patient care is up to date